5/13
08:09 am
xfor
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference [Yahoo! Finance]
Medium
Report
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference [Yahoo! Finance]
5/13
08:00 am
xfor
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
Medium
Report
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
5/9
06:44 am
xfor
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility [Yahoo! Finance]
Medium
Report
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility [Yahoo! Finance]
5/9
06:30 am
xfor
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
Low
Report
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan Facility
5/8
11:24 am
xfor
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
Low
Report
X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Q1 2024 Earnings Call Transcript [Yahoo! Finance]
5/7
06:14 am
xfor
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
Medium
Report
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates [Yahoo! Finance]
5/7
06:01 am
xfor
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
Medium
Report
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate Updates
5/1
04:09 pm
xfor
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
5/1
04:05 pm
xfor
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/30
08:17 am
xfor
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024 [Yahoo! Finance]
Medium
Report
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024 [Yahoo! Finance]
4/30
08:12 am
xfor
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target raised by analysts at HC Wainwright from $3.00 to $5.00. They now have a "buy" rating on the stock.
Medium
Report
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its price target raised by analysts at HC Wainwright from $3.00 to $5.00. They now have a "buy" rating on the stock.
4/30
08:00 am
xfor
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
Medium
Report
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024
4/29
05:25 pm
xfor
X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside [Seeking Alpha]
Neutral
Report
X4 Pharmaceuticals: FDA Approval For WHIM Warrants Further Upside [Seeking Alpha]
4/29
12:36 pm
xfor
PANTHERx® Rare Partnering with X4 Pharmaceuticals Inc. for the Distribution of XOLREMDI™ (mavorixafor), the First FDA-Approved Therapy Indicated for Use in Patients with WHIM Syndrome [Yahoo! Finance]
Medium
Report
PANTHERx® Rare Partnering with X4 Pharmaceuticals Inc. for the Distribution of XOLREMDI™ (mavorixafor), the First FDA-Approved Therapy Indicated for Use in Patients with WHIM Syndrome [Yahoo! Finance]
4/29
06:42 am
xfor
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome [Yahoo! Finance]
High
Report
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome [Yahoo! Finance]
4/29
06:30 am
xfor
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
High
Report
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM Syndrome
4/15
06:57 pm
xfor
X4 Pharmaceuticals: PDUFA Excitement Ahead [Seeking Alpha]
Medium
Report
X4 Pharmaceuticals: PDUFA Excitement Ahead [Seeking Alpha]
4/11
10:37 am
xfor
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns [Yahoo! Finance]
Low
Report
X4 Pharmaceuticals, Inc.'s (NASDAQ:XFOR) market cap decline of US$42m may not have as much of an impact on institutional owners after a year of 7.0% returns [Yahoo! Finance]
4/2
04:05 pm
xfor
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/1
08:00 am
xfor
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
Low
Report
X4 Pharmaceuticals to Participate in Upcoming April Investor Conferences
3/22
03:44 pm
xfor
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Low
Report
X4 Pharmaceuticals, Inc. (NASDAQ: XFOR) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
3/21
06:09 am
xfor
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
High
Report
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update [Yahoo! Finance]
3/21
06:01 am
xfor
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
High
Report
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate Update
3/12
08:00 am
xfor
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
Low
Report
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024
3/1
04:12 pm
xfor
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Medium
Report
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]